Testosterone therapy for low testosterone in men with low-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older.
- You have low-risk or favorable intermediate-risk prostate cancer and are being watched closely (active surveillance).
- You do not have high-risk or very high-risk prostate cancer.
- You do not have conditions that make testosterone therapy unsafe, such as advanced prostate cancer, male breast cancer, or poorly controlled heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests whether an exercise program can help men with early-stage prostate cancer who are being monitored instead of treated. If you are not very active now, you may be able to join a structured exercise plan to see if it improves your health and cancer signs.
This study tests whether tamoxifen (a hormone-blocking medication) can help men's testosterone levels recover after they finish androgen deprivation therapy (ADT)—a common prostate cancer treatment that lowers testosterone. The goal is to see if tamoxifen can safely speed up testosterone recovery and improve quality of life.
This study tests whether testosterone replacement therapy can safely improve low testosterone symptoms in men with low-risk prostate cancer who are not receiving active treatment. You may be eligible if you have confirmed low testosterone and are being monitored without intervention.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
Hear when a new Stage I Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.